



Contact: Michael Cardone
Location: Cambridge, MA
Email: mcardone@eutropics.com
Tel: 617-714-4405
Website: www.eutropics.com



Company Overview

Industry Sector: Oncology Companion Diagnostic/Therapeutic

Company Overview: Eutropics Pharmaceuticals, Inc. is an early stage biopharmaceutical company that is developing drugs for the treatment of cancer and a companion diagnostic assay licensed from the Dana Farber Cancer Institute (DFCI). Eutropics' first in class compounds selectively trigger apoptosis in cancer cells while our proprietary diagnostic assay, BH3 identifies cancer patients who are most likely to respond to this new class of compounds as well as other experimental and standard of care treatments.

Target Market(s): Partnering pharmaceutical and diagnostics companies as well as oncology physicians, patients and payers

Key Value Drivers

Technology*: Eutropics is using high resolution biochemical assays and computational models as well as the insights from the BH3 profiling technology to guide the SAR of our lead compound series. Our approach enables identification of highly targeted compounds that surpass those from competing programs.

Competitive Advantage: Eutropics has discovered a compound that is highly active against myeloid cell factor 1 (Mcl-1) recognized as a key factor in causing blood and other cancers. In parallel we have developed proprietary assays to determine if a cancer cell is in fact dependent on this protein for survival, or whether the cancer cell is dependent on other proteins. These assays both enable the development of the drugs that accurately target these proteins to trigger tumor cell death and predict when they will work. Thus, these assays are translational tools from the bench to the clinic that allow the identification of patients whose tumors are most likely to respond to a given therapeutic, thereby accelerating clinical progress and leading to more specific and effective drugs.

Plan & Strategy: Eutropics is in discussion with potential pharma partners who will support the clinical development of lead compound and of our diagnostic test.

Management

Leadership:
 Michael Cardone, PhD, President and CEO
 David Richard, PhD, Director of Drug Development
 Tom Atwood, MBA, Chief Financial Officer
 Bill Pierceall, PhD, Director of Oncology

Business Advisory Board
 Maggie LeFlore, PhD Partner MedImmune Ventures
 Phyllis Whiteley, PhD Executive in Residence Mohr Davidow
 Robert Curtis, PharmD, Former CEO HistoRx
 Giulio Draetta, MD, PhD Director of Applied Cancer Research MD Anderson

Scientific Advisory Board:
 Anthony Letai, MD, Ph.D. (Co-founder) Professor of Medicine at DFCI
 Ken Anderson, MD, Professor of Medicine at DFCI
 Alan D'Andrea: Professor of Medicine at DFCI
 Gerhard Wagner, PhD. Professor of Biophysics and Pharmacology at Harvard
 Michael Andreeff, MD, PhD, Professor of Medicine at MD Anderson
 Lames Bradner, MD, PhD, Professor of Medicine at DFCI

Eutropics Product Pipeline

DISEASE	Mcl-1 Drug Candidates	On target Efficacy-Cell Culture	Safety-PK Animals	Efficacy Animals	IND-enabling
Multiple Myeloma	EU-4030	[Progress bar from On target Efficacy-Cell Culture to IND-enabling]			
Multiple Myeloma	EU-5013	[Progress bar from On target Efficacy-Cell Culture to Efficacy Animals]			
AML	EU-4030	[Progress bar from On target Efficacy-Cell Culture to Safety-PK Animals]			
Prostate Cancer	EU-5013	[Progress bar from On target Efficacy-Cell Culture to Safety-PK Animals]			

DISEASE	Companion Diagnostic for:	Readout correlation Efficacy(cells/mice)	Initial Clinical test ,verification	Expanded Clinical test Cutoff Validation
Multiple Myeloma	EU-4030 EU-5013	[Progress bar from Readout correlation Efficacy to Expanded Clinical test Cutoff Validation]		
Multiple Myeloma	Velcade (RVD)	[Progress bar from Readout correlation Efficacy to Initial Clinical test ,verification]		
Multiple Myeloma	HDAC-In CDK-1 In	[Progress bar from Readout correlation Efficacy to Initial Clinical test ,verification]		
AML	Cytarabine HDAC In	[Progress bar from Readout correlation Efficacy to Initial Clinical test ,verification]		
AML	EU-4030 EU-5013	[Progress bar from Readout correlation Efficacy to Initial Clinical test ,verification]		